Document Detail


Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability.
MedLine Citation:
PMID:  18448096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cyclooxygenase-2 (COX-2) is expressed in rheumatoid and osteoarthritic cartilage and produces pro-inflammatory prostanoids in the joint. In the present study, we investigated the effects of disease modifying anti-rheumatic drugs on COX-2 expression in chondrocytes. Unlike the other tested drugs, aurothiomalate was found to inhibit COX-2 expression in chondrocytes. In the further studies, effects and mechanisms of action of aurothiomalate were investigated in more detail. Aurothiomalate inhibited IL-1beta-induced COX-2 protein expression and PGE(2) production in chondrocytes in a dose-dependent manner. Because aurothiomalate did not alter IL-1beta-induced mRNA levels when measured 0-3 h after addition of IL-1beta, its effects on COX-2 mRNA degradation were tested by Actinomycin D assay. The half-life of COX-2 mRNA was reduced from 3 h to less than 1.5 h in aurothiomalate-treated cells. The 3'-untranslated region (3'-UTR) of COX-2 mRNA contains an ARE element which has been shown to bind mRNA stabilizing factor HuR. Interestingly, aurothiomalate inhibited HuR expression which may explain its destabilizing effect on COX-2 mRNA. Aurothiomalate reduced COX-2 expression and PGE(2) production also in human cartilage at drug concentrations which have been measured in serum and synovial fluid during treatment with aurothiomalate. The results show that aurothiomalate reduces COX-2 expression and PGE(2) production in chondrocyte cultures and in human cartilage. The action is likely mediated by enhanced COX-2 mRNA degradation possibly through a mechanism related to reduced expression of HuR. The results provide a novel mechanism of action for aurothiomalate which may be important in the treatment of arthritis.
Authors:
Riina Nieminen; Katriina Vuolteenaho; Asko Riutta; Hannu Kankaanranta; Peter M van der Kraan; Teemu Moilanen; Eeva Moilanen
Related Documents :
11443626 - Relation between cyclooxygenase-2 expression and tumor invasiveness and patient surviva...
24385536 - Unbiased rnai screen for hepcidin regulators links hepcidin suppression to the prolifer...
9680006 - Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappab.
19320776 - Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atheroscleros...
21109746 - Flagellin induces the expression of thymic stromal lymphopoietin in human keratinocytes...
19427096 - Hematopoietic- and neurologic-expressed sequence 1 (hn1) depletion in b16.f10 melanoma ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-03-29
Journal Detail:
Title:  European journal of pharmacology     Volume:  587     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-02     Completed Date:  2008-08-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  309-16     Citation Subset:  IM    
Affiliation:
The Immunopharmacology Research Group, Medical School, University of Tampere and Research Unit, Tampere University Hospital, Tampere, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antirheumatic Agents / pharmacology*
Blotting, Western
Cartilage / drug effects,  enzymology*,  pathology
Chondrocytes / drug effects,  enzymology*
Cyclooxygenase 2 / biosynthesis*
Cyclooxygenase 2 Inhibitors*
Dinoprostone / biosynthesis
Dose-Response Relationship, Drug
Drug Interactions
Gold Sodium Thiomalate / pharmacology*
Humans
RNA, Messenger / biosynthesis,  genetics
Reverse Transcriptase Polymerase Chain Reaction
Tetrazolium Salts
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Cyclooxygenase 2 Inhibitors; 0/RNA, Messenger; 0/Tetrazolium Salts; 117038-70-7/2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; 12244-57-4/Gold Sodium Thiomalate; 363-24-6/Dinoprostone; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression...
Next Document:  Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing ...